STEM-Talk cover image

STEM-Talk

Latest episodes

undefined
Apr 29, 2020 • 54min

Episode 106: Francisco Gonzalez-Lima talks about brain metabolic mapping and Alzheimer’s

Our guest today is Dr. Francisco Gonzalez-Lima, a professor in the department of psychology, pharmacology and toxicology and the department of psychiatry at The University of Texas at Austin. He also is a professor at the university’s Institute for Neuroscience. We covered so much ground in our discussion with Francisco that we have split his interview into two parts. Today’s interview focuses on Francisco’s fascinating background as a youth and Cuban expatriate as well as his early research into Alzheimer’s Disease and brain metabolic mapping. The second part of our interview, which follows in a few weeks, covers two interventions Francisco has been exploring with the aim of protecting people against neurodegeneration: low-dose methylene blue and the application of near-infrared light. Francisco describes himself as a behavioral neuroscientist. He and his colleagues at the Gonzalez-Lima Lab are recognized as world leaders for their research on the relationship between brain energy metabolism, memory and neurobehavioral disorders. Although he has spent most of his academic career at the University of Texas, Francisco has been a visiting neuroscientist in Germany, England, Canada and Spain, and has delivered more than 120 lectures around the world about his brain research. He also has contributed work to more than 300 scientific publications. Over the years, Francisco’s brain research has focused on transcranial lasers, memory enhancement, neuroprotection and neurocognitive disorders. Current research in the Gonzalez-Lima laboratory focuses on the beneficial neurocognitive and emotional effects of noninvasive human brain stimulation in healthy, aging and mentally ill populations. This research primarily uses transcranial infrared laser stimulation and multimodal imaging. Show notes: [00:03:23] Dawn opens the interview mentioning that Francisco was born in Cuba where his father worked as a veterinarian. Dawn asks how Francisco’s family ended up leaving Cuba for Costa Rica when he was only ten years old. [00:04:25] Ken asks if it is true that Francisco got into a lot of fights as a child. [00:05:19] Francisco talks about his time as a child accompanying his veterinarian father to take care of cattle. [00:06:46] Dawn asks about Francisco’s time in college, two years of which he spent in Venezuela, and how he became known as an anti-communist student leader on campus. [00:08:18] Francisco tells the story of how he ended up going to school at Tulane University. [00:09:13] Dawn mentions that because Francisco’s father was a veterinarian, Francisco went to Tulane with the intent of working with animals. But after watching a professor dissect a human brain in class one day, Francisco changed his major. [00:10:17] Ken asks Francisco what lead him to decide to get a bachelor’s degree in biology and psychology. [00:11:49] Dawn asks about Francisco’s work with Nobel Prize winner Dr. Andrew Schalley during Francisco’s last summer at Tulane. [00:12:56] Francisco explains how he ended up of the University of Puerto Rico getting his doctorate in anatomy and neurobiology. [00:14:28] Dawn asks Francisco how learning about electrophysiology in his doctoral studies had an impact on him. [00:15:22] Francisco tells an interesting story of his doctoral dissertation. [00:16:21] Dawn asks about Francisco’s work with Dr. Walter Stiehl and the papers the two of them published in the European Journal of Pharmacology. [00:17:19] Dawn mentions that in 1981 Francisco met Henning Scheich, a German professor who had done a study involving the newly developed 2-deoxyglucose autoradiographic method. Francisco talks about why this neuroimaging approach to brain research fascinated him and led him to propose an ambitious collaborative research project with Dr. Scheich. [00:18:27] Dawn asks Francisco to talk about the work he did with Dr. Scheich to develop the human FDG (fluorodeoxyglucose) neuroimaging method, the first functional brain imaging technique to be used in humans. [00:19:58] Ken asks Francisco to explain the difference between functional studies and imaging studies. [00:21:18] Dawn asks about how Francisco met a group of Texas professors at a conference in Madrid, which lead him to join the new College of Medicine at Texas A&M. [00:22:35] Dawn mentions that in 1991, the University of Texas at Austin recruited Francisco to join its new Institute for Neuroscience and the Department of Psychology. [00:23:32] Dawn asks about the research Francisco and his colleagues are doing in the Gonzalez-Lima lab. [00:24:11] Ken asks what Francisco means when he describes himself as a behavioral neuroscientist. [00:25:13] Dawn asks about Francisco’s work on the neuroimaging effects of Pavlovian conditioning. [00:27:45] Dawn asks about the work Francisco did on habituation and sensitization. [00:29:57] Ken mentions that the brain is designed to handle large amounts of communication and computation. He asks if Francisco can elaborate on this concept. [00:31:10] Ken asks Francisco to describe the redundant structures of the brain. [00:33:35] Dawn turns the discussion to Alzheimer’s Disease, mentioning we still don’t fully grasp how the brain works. [00:35:12] Dawn mentions that in 2001 Francisco published a paper titled “Energy Hypometabolism in Posterior Cingulate Cortex of Alzheimer’s Patients: Superficial Laminar Cytochrome Oxidase Associated with Disease Duration.” The main histochemical finding of this study was that the decreased ration or the gravity of Alzheimer’s Disease was not related to any of the other things that were commonly mentioned like amyloid or tau proteins. Francisco gives an overview of this study and its significance. [00:39:32] Ken asks if ketone uptake in the brain diminishes some cases of Alzheimer’s or TBI. [00:41:18] Ken mentions Steven Cunane’s STEM-Talk interview and the work he has done work using neuroimaging to see if it’s possible to replace the energy lost from the glucose deficit with exogenous ketones. [00:42:11] Ken asks about the early signs of Alzheimer’s Disease. [00:45:27] Ken asks about the vascular hypothesis of Alzheimer’s Disease. [00:48:16] Dawn mentions that in the past few years, there has been a lot of coverage in the media about Early Onset Alzheimer’s Disease. She goes on to say that Francisco has pointed out in past interviews that EOAD is a rare genetic disease that is causally different than the most common geriatric dementia that is mistakenly called Alzheimer’s or late onset AD. Francisco discusses how this confusion has been an obstacle in advancing research. [00:52:24] Dawn gives a preview of part two of our interview with Francisco, which will upload in a few weeks. Links: Francisco Gonzalez-Lima bio Gonzalez-Lima Lab Learn more about IHMC STEM-Talk homepage  Ken Ford bio Dawn Kernagis bio      
undefined
Apr 7, 2020 • 48min

Episode 105: Art De Vany talks about healthspan, lifespan and healing the wounds of aging

Our guest today is Dr. Arthur De Vany, who we interviewed three years ago on episode 30 of STEM-Talk. Art, who is perhaps best known as one of the founders of the Paleo movement, is the author of “The New Evolution Diet: What Our Paleolithic Ancestors Can Teach Us About Weight Loss, Fitness and Aging.” Art is a professor emeritus of economics at the University of California, Irvine. In our first interview, we talked to Art about his early research into the economics of the movie business and how he created mathematical and statistical models to precisely describe the motion-picture market. In today’s interview, Art talks to us about the new book he’s working on that’s tentatively titled, “The Youthful Brain—A Revolutionary Program to protect the Brain, Extend Youthfulness and Prevent Alzheimer’s Disease.” The book is a continuation of Art’s ongoing study of the human body and brain and offers his strategies for preventing brain deterioration and maintaining a healthy, lean body. Show notes: [00:03:13] Dawn opens the interview mentioning that it has been three years since Art’s first appearance on the podcast. She asks Art what it is about the modern Western lifestyle that sends so many people to an early grave. [00:05:42] Dawn asks about Art’s discovery that the world’s healthiest, long-living individuals typically have low insulin. [00:07:44] Ken mentions that Art is working on a new book that will look at brain-body signaling and provide strategies for preventing brain deterioration and maintaining a healthy lean body. Art talks about how we originally planned to write about aging, but that most aging research is bull and that nobody really understands what it is. He explains that in his mind aging is basically a directed random walk into entropy. [00:10:11] Ken asks about one of Art’s key points, that Alzheimer’s disease and many other diseases of neural degeneration and cognitive decline are largely metabolic diseases compounded by loss of muscle mass and stem-cell exhaustion. [00:13:09] Dawn asks about the evolution of the human brain, and how the most recent additions to the brain are the most dependent on glucose metabolism. [00:14:22] Dawn mentions that synapses are essential to neuronal function, as they are the means by which neurons communicate signals. She asks Art to expand on the comment he made in his recent lecture at IHMC stating that “synapses are forever young but in ever need of support and protection.” [00:16:29] Ken asks about the lactate shuttle hypothesis, which is based on the observation that lactate is formed and utilized continuously in diverse cells under both anaerobic and aerobic conditions. [00:18:51] Dawn mentions the role of mitochondria, and how when they are not working the way they should that cells and tissues of our body become starved for energy, forcing us to rely on anaerobic metabolism. This results in a number of issues. She asks Art what we can do to maintain healthy mitochondria over our lifespan. [00:21:25] Art gives advice for reprograming the metabolism of the aging brain. [00:22:35] Ken asks about mTOR from an evolutionary perspective and why people have so many concerns regarding its role in cancer and degenerative disease. [00:24:35] Art explains his view of aging as the “failure of a renewal program,” and why aging is not programmed. [00:26:35] Dawn mentions that she has heard that Art eats just two meals a day, an early breakfast and dinner, to create a long interval between meals so his body can maintain low-insulin signaling. She asks how this brings on the defensive and repair pathways. [00:28:52] Ken asks about Art’s exercise routine and why he prefers fasted exercise. [00:30:46] Dawn asks about the importance of sleep, if Art still takes melatonin to help with his sleep, and what advice he has for people in terms of getting good sleep. [00:32:56] Dawn mentions that Art has commented that physically and genetically we are built to run fast and climb trees, but given the state of the modern world she asks what is the best way to stay physically fit if we are not allowed to regularly do those things that we evolved to do. [00:35:47] Ken asks for Art’s thoughts on why we have seen the loss of mass in the human brain, particularly in the hippocampus. [00:41:44] Ken asks about the role of oxytocin in preserving brain mass. [00:43:02] Dawn points out that Art is 82 years old. If aging is indeed a random walk into entropy, she asks Art what he considers a reasonable expectation is in terms of human lifespan. [00:43:50] Dawn mentions that Art has in the past said that he was 78 years old when he first started thinking about aging.  Given that most people start having those thoughts in their 60s, she asks why it took him so long. [00:44:55] Ken closes the interview asking Art what advice he would give to his younger self. Links: Art De Vany Amazon page Learn more about IHMC STEM-Talk homepage  Ken Ford bio Dawn Kernagis bio
undefined
Mar 10, 2020 • 1h

Episode 104:  Katherine Eban talks about the dangers associated with relying on generic drugs manufactured overseas

Today’s interview is with Katherine Eban, an investigative journalist who uncovered the widespread fraud that goes on overseas in the manufacturing of U.S. generic drugs. With the outbreak of the deadly coronavirus, which originated in China but is now spreading across the globe and United States, today’s interview is especially timely. Katherine’s recent book, “Bottle of Lies,” reveals that nearly 80 percent of the active ingredients of all brand-name and generic drugs as well as almost all of our antibiotics in the U.S. are made outside of the country, mostly in China and India. Today’s interview highlights the dangers Americans face in outsourcing the quality and safety of its brand-name and generic drugs to overseas manufacturers. Katherine is an investigative journalist who has written award-winning stories that range from pharmaceutical counterfeiting to gun trafficking to even coercive interrogations by the CIA. Her first book, “Dangerous Doses: A True Story of Cops, Counterfeiters and the Contamination of America’s Drug Supply,” was named one of the Best Books of 2005 by Kirkus Reviews. “Bottle of Lies: The Inside Story of the Generic Drug Boom” is a New York Times bestseller that came out in 2019 and was named one of the top 100 notable books of 2019 by the Times. Show notes: [00:03:16] Dawn opens the interview mentioning Katherine’s appearance on Peter Attia’s podcast. [00:04:30] Ken asks how Katherine how she ended up living just three subway stops from where she grew up in Brooklyn. [00:05:01] Katherine talks about how despite her talent and interest in writing, she at one point joined the circus in high school and considered going to clown school after she graduated. [00:06:02] Dawn asks how Katherine ended up in Rhode Island to attend Brown University instead of going to Florida to attend the Ringling Brothers Clown College. [00:06:47] Katherine talks about her time at Brown University editing the school’s literary magazine. [00:07:24] Ken Asks about Katherine’s time at Oxford University as a Rhodes scholar. [00:08:37] Dawn asks how Katherine, a woman who holds a Master’s degree in 17th Century English Epic Civil War Poetry, became a journalist. [00:10:23] Dawn asks about Katherine’s first big story, which also happened to be her first story. [00:11:49] Dawn asks Catherine long she worked at the New York Times. [00:13:07] Katherine explains how she came to write her first book, “Dangerous Doses: A True Story of Cops, Counterfeiters and the Contamination of America’s Drug Supply.” [00:14:56] Dawn mentions that after the publishing of “Dangerous Doses,” Katherine spent a decade investigating the generic-drug industry, an investigation sparked by a phone call from a colleague who asked for her help. [00:16:17] Ken asks about the difference between a generic and brand-name drug, and what is involved in the process of reverse-engineering a drug. [00:17:43] Dawn asks about the series of interviews Katherine conducted with patients sharing their experiences with generic drugs, which led to a story she wrote for “Self” magazine in 2009. [00:20:15] Ken mentions that in the “Self” magazine article, Katherine wrote about Dr. Kesselheim, an instructor at Harvard Medical school who reviewed data from 47 clinical studies. He found no evidence that patients on brand-name cardiovascular drugs had outcomes superior to those on generics. Given this study is now 10 years old, Ken asks if anyone has revisited this analysis. [00:21:25] Katherine tells the story of her anonymous informant that contacted her about a month after the “Self” magazine article, who went by the pseudonym “4 Dollar Refill.” [00:22:38] Dawn mentions that over the following five years, Katherine wrote a series of articles about generic-drug quality, which culminated in a 10,000-word article titled “Dirty Medicine” published in Fortune Magazine in 2013. [00:24:03] Dawn mentions that a reason that generic drugs account for 90% of the drugs in the U.S. is that generics are so much cheaper than brand names. She goes on to ask about how in “Bottle of Lies” Katherine explains why the low cost of manufacturing in India and China has created issues for the American consumer. [00:25:08] Dawn asks about the Carnegie Fellowship Katherine received in the midst of working on “Bottle of Lies.” [00:26:42] Ken asks Katherine how many interviews she had to do for her book. [00:27:11] Katherine talks about how the plan to help Africa during the AIDS epidemic laid the groundwork for some of the corruption she laid out in “Bottle of Lies.” [00:29:14] Katherine tells the story of Harry Lever, a cardiologist at the Cleveland Clinic, who started noticing his patients suffering from low platelet count after taking heparin, which raised his concerns, and led him to discover that heparin had been contaminated in China. [00:30:10] Ken asks what the average person can expect if they tell their pharmacist that they do not want the generic version of a drug that their doctor prescribed. [00:31:26] Dawn asks if this problem is being substantially driven by insurance companies. [00:31:56] Ken asks what it was that caused generic drugs to make up 90% of the drug supply today, when in 2009 they only made up 60%. [00:33:16] Dawn asks about Peter Baker, a young FDA investigator, who ended up in New Delhi looking into Indian drug manufacturers. [00:34:17] Ken asks about the obstacles Peter Baker faced. [00:36:47] Katherine explains what the protocol is when an FDA investigator finds contamination. [00:38:18] Dawn asks about Peter Baker’s investigation into the Wockhardt plant. [00:41:22] Ken asks Katherine to tell the story of Ranbaxy, India’s largest drug company. [00:44:27] Katherine how Dinesh Thakur became a whistleblower. [00:45:51] Ken asks what happened to Ranbaxy. [00:46:29] Katherine explains why Peter Baker eventually left the FDA despite the good work he was doing. [00:48:18] Dawn mentions that in light of Baker’s and other FDA investigators’ discoveries of fraud and corruption in China and India, stronger regulations are needed in order to protect consumers. She asks if Katherine has a sense of what direction the FDA is headed in that regard. [00:49:39] Ken asks if we should start producing more of our own drugs in the U.S. [00:50:30] Katherine explains the resource on her website titled “A Guide to Investigating Your Own Drugs.” [00:52:21] Dawn asks about Valisure, a mail-order pharmacy that tests every drug that they dispense to ensure quality. [00:54:18] Dawn mentions that Katherine was recently in India to do some talks and book signings, but that she had concerns about the reception because the Modi Government had put out a statement saying that it was going to take action against her book. [00:55:39] Ken asks if Katherine is working on any new projects at the moment. [00:56:13] Ken asks if Katherine is still in touch with Harry Lever at the Cleveland Clinic, or “4 Dollar Refill.” [00:56:47] Dawn closes the interview asking about Katherine’s 187-pound dog Romeo. Links: Katherine Eban website Learn more about IHMC STEM-Talk homepage Ken Ford bio Dawn Kernagis bio    
undefined
Feb 19, 2020 • 1h 48min

Episode 103: Abe Morgentaler talks about men’s health, sex drive and the benefits of testosterone therapy

Today’s interview is with Dr. Abraham Morgentaler, an internationally known pioneer in men’s sexuality and the founder of the first comprehensive center in the U.S. specializing in men’s health. Abe’s research has upended longstanding concepts regarding testosterone therapy, prostrate cancer and male sexuality.  He is particularly credited with research that has contradicted the established view that testosterone injections led to elevated risks for prostate cancer. In today’s interview, we talk to Abe about testosterone deficiency and its effects on men’s health and sex drive; the biological functions of testosterone; and Abe’s work treating metastatic prostrate cancer. Abe is the director of Men’s Health Boston and an associate clinical professor of Urology at Harvard Medical School. He is the author of “Why Men Fake It: The Totally Unexpected Truth About Men and Sex,” which was retitled “The Truth About Men and Sex” for the paperback edition. He also is the author of “Testosterone for Life: Recharge Your Vitality, Sex Drive, Muscle Mass and Overall Health.” Show notes [00:02:58] Dawn opens the interview mentioning that Abe grew up in Canada, asking him what his interests were as a kid other than hockey. [00:04:28] Dawn asks what Abe’s gap year between high school and college was like. [00:07:48] Abe explains that when he was born, his mother had some specific wishes for him. He failed at one but came through on the other. [00:08:17] While a sophomore in college trying to find his way, Abe ended up studying sex hormones in lizards. [00:16:32] Dawn explains that for a long time the greatest fear related to the use of testosterone therapy was that it would lead to prostate cancer. This was based on a 1941 paper by Charles Huggins from the University of Chicago, who wrote that his research found cancers were sensitive to hormonal manipulation. Dawn asks Abe to discuss how he started questioning this long-held dogma that high testosterone levels caused prostate cancer. [00:23:29] Dawn mentions that this story is a great example of why it is important in science to question things, particularly the status quo. [00:31:50] Abe talks about his 2006 paper, “Testosterone and Prostate Cancer, a Historical Myth,” which showed that the data contradicted the old belief that more testosterone would lead to more prostate growth. [00:40:10] Ken mentions that Abe followed up his previously mentioned paper with another one titled, “The Saturation Model and the Limits of Androgen-Dependent Growth.” [00:45:19] Abe talks about the exciting work he is doing helping men deal with metastatic prostate cancer. [00:51:32] Dawn explains how Abe uses the term “low T” to describe a condition that is otherwise known as hypogonadism or testosterone deficiency syndrome. Abe describes the many biological functions of testosterone. [00:53:27] Abe responds to the criticism that because testosterone levels decline with age, the process must be natural and, therefore, should not be treated. [00:55:42] Abe discusses a paper that came out in 2013 in the Journal of the American Medical Association that reported increased cardiovascular risk in men given testosterone replacement, and how the study’s statistical analysis was seriously flawed. [01:07:03] Ken mentions that in 2017, a trial by Budoff et al., published in JAMA, suggested that testosterone replacement therapy in men with low T led to more rapid progression of atherosclerotic plaques compared to placebo. [01:13:21] Ken asks why Abe thinks that testosterone replacement therapy can actually be protective in regards to cardiovascular disease. [01:14:19] Ken asks about the seemingly rapid drop in testosterone levels in men in the western world as reported by several papers including the Massachusetts Male Aging Study, as well as a large Finnish Study, and a 2017 meta-analysis. [01:17:37] Dawn mentions that while most people are aware of the term menopause, most are less familiar with the term andropause, coined as the male equivalent. [01:20:41] Abe explains why blood tests for low T can be deceiving, and alternative tests that produce more practical results. [01:25:55] Dawn asks about Men’s Health Boston, which Abe founded in 1999, which was the first comprehensive men’s health center in the United States. [01:29:18] Ken asks about the different modes and types of testosterone administration. [01:33:21] Ken asks about the fears of the aromatization of testosterone to estrogen with replacement therapy. [01:36:14] Ken asks if there are any studies looking into “super physiological” levels of testosterone, such as levels up to 2000. [01:39:22] Ken mentions that in Abe’s book “The Truth About Men and Sex,” Abe explains that his attempt was to pull back the curtain to reveal men as they truly are, the last chapter being titled, “Men Are People, Too.” [01:43:19] Dawn asks Abe what he likes to do in his spare time. [01:45:36] Dawn mentions that Abe was 18 when he entered Harvard as a freshman, and asks him if he had any idea that he would still be at Harvard more than four decades later.
undefined
Jan 28, 2020 • 48min

Episode 102: Adam Konopka talks about metformin’s effects on healthspan and lifespan

Our guest today is Dr. Adam Konopka, an assistant professor in the Department of Kinesiology and Community Health at the University of Illinois Urbana Champaign, who believes that aging is the greatest risk factor for just about every single chronic disease that exists. Adam’s lab, called the Musculoskeletal Aging and Metabolism Lab, is focused on aging-related research. In addition to doing research that looks at different ways to delay the onset of age-related diseases and functional decline, Adam also has done a lot of research related to the interaction of exercise with metformin. Adam and his colleagues had a paper in Aging Cell that suggested metformin may blunt the health benefits of exercise in healthy older adults, a study that attracted a lot of attention and was highlighted in a story in The New York Times back in June. Show notes: [00:03:59] Dawn opens the interview mentioning that Adam’s lab is at the University of Illinois, and asks if he decided on Illinois because he grew up in a suburb outside of Chicago. [00:04:28] Dawn asks Adam how he ended up getting into competitive swimming. [00:05:13] Adam explains how his involvement in swimming increased his curiosity about physiology and ways to improve performance, a line of thought that contributed to his eventual majoring in exercise science. [00:05:49] Dawn asks Adam why he decided to minor in entrepreneurship. [00:06:18] Dawn asks Adam about the time when a professor doing research in pediatrics gave Adam the opportunity to volunteer for a study. [00:07:01] Ken mentions that while Adam was a student, he had the opportunity to work on a study which looked at an exercise program used by crew members aboard the International Space Station. Adam explains what his role in this study was. [00:08:05] Adam talks about his time spent at the Mayo Clinic as a postdoctoral research fellow, where he focused his time on looking at skeletal muscle mitochondrial function. [00:09:00] Dawn explains Adam’s notion that mitochondria contribute to obesity induced insulin resistance, a highly debated topic. Dawn goes on to mention Adam’s 2015 paper that looked at obese women who had defects in mitochondrial efficiency and hydrogen peroxide emissions. Adam explains how exercise effectively restored the mitochondrial physiology of these women to that of a leaner phenotype. [00:10:36] Adam discusses a metformin study he was a part of while at the Mayo Clinic, where he tested a hypothesis that had been previously shown in cell culture, to learn if those findings were translatable to humans. [00:11:51] Adam talks about the significance of his findings that metformin improved fasting and postprandial glycemia without inhibiting glucagon-stimulated glucose production. [00:12:59] Ken asks about the two and a half years Adam spent at Colorado State and the research that he conducted there. [00:13:32] Adam explains the mission of, and the research being done at, his lab, The Musculoskeletal Aging and Metabolism Lab, at the University of Illinois. [00:16:25] Ken asks Adam if he has looked into rapamycin and muscle, with respect to mTOR inhibition. [00:17:01] Dawn mentions that Adam took these earlier studies, as well as the research he did as a postdoc, and started asking questions related to the interaction of exercise with metformin. [00:17:30] Ken mentions how this research led to Adam’s paper earlier this year, which was highlighted in the New York Times, and which cast doubt on the idea that exercise and metformin, both of which have been looked at in the context of healthspan extension, work well together in conjunction. [00:19:24] Dawn asks if the negative effects of metformin documented in various studies are relatively modest and or negligible. [00:20:30] Ken asks Adam to speculate on some of his findings, particularly why a certain portion of individuals dosed with metformin are likely to be negative-responders, but at the same time others are positive-responders. Adam talks on this wide variability in the response to metformin. [00:23:12] Dawn asks about Adam’s follow-up research into exercise and metformin that he received a grant for. [00:25:20] Ken mentions it has been suggested that people space out the taking of metformin from the time a person exercises, given that the half-life of metformin is six hours. [00:27:03] Dawn asks if the widely reported health benefits of metformin are worth it possibly inhibiting beneficial mitochondrial adaptations to exercise in older adults. [00:28:38] Dawn asks for Adam to speculate on the mechanisms behind how metformin blunts the adaptive response to exercise. [00:30:48] Ken talks in regards to the NIH-funded trial into metformin called, “Targeting Aging with Metformin” or TAME. Ken asks about Adam’s paper in GeroScience titled, “Taming Expectations of Metformin as a Treatment to Extend Healthspan.” [00:32:57] Ken mentions that he would have liked to have seen rapamycin used instead of metformin in the TAME trial. [00:33:42] Dawn asks if Adam believes that a metformin trial in healthy individuals is currently warranted. [00:34:38] Dawn mentions that while metformin undoubtedly helps individuals suffering from metabolic disease, it is unclear if it has any significant positive effects on already healthy individuals. She goes on to mention that this is paradoxical in light of the fact that the majority of popular interest in off-label use of metformin is in healthy individuals or the so called “worried well,” people who already follow habits of good health. [00:36:16] Ken asks Adam how, in a perfect world, he would design a trial for healthspan-extending intervention in regards to what intervention would he pick, and how he would gauge efficacy considering that an intervention in healthy individuals would ideally need to be continued for several decades in order to determine a true effect. Ken goes on to ask what the pros and cons are of proxies for age in such a study including telomere length as well as biological and epigenetic clocks. [00:39:26] Ken asks how Adam would adjust for lifestyle behaviors like dietary manipulation and exercise that activate similar pathways to drugs like metformin and rapamycin in his hypothetical study. [00:40:44] Dawn asks if Adam has much expectation in extending lifespan with pharmacological methods, or if he thinks that merely healthspan will increase while we see a so-called compression of morbidity, and if he thinks that these pharmacological treatments are likely to surpass lifestyle interventions like exercise. [00:42:39] Ken asks if Adam has looked at PPAR-D agonists, which are a class of drugs that provide some of the effects of exercise pharmacologically. [00:43:50] Adam gives his advice to people interested in extending their healthspan. [00:44:57] Dawn asks what Adam’s diet and exercise routine look like. [00:46:11] Dawn mentions that she knows that Adam and his wife have a young child and closes the interview asking Adam what he does for fun in his spare time. Links: Adam Konopka bio Musculoskeletal Aging and Metabolism Lab Facebook page Learn more about IHMC STEM-Talk homepage  Ken Ford bio Dawn Kernagis bio  
undefined
Jan 7, 2020 • 0sec

Episode 101: Rachel Yehuda talks about epigenetic inheritance, PTSD and the potential of MDMA therapies

Today we talk with Dr. Rachel Yehuda whose pioneering research on cortisol and brain function has revolutionized worldwide our understanding and treatment of post-traumatic stress disorder. Rachel is also well-known for her studies on the intergenerational transmission of trauma and PTSD. This novel research has shown that the children of traumatized parents are at risk of similar problems due to epigenetic changes that are transmitted from the parents to their offspring. She has worked with war veterans, Holocaust survivors and other victims of trauma to detail the biological roots of PTSD. She is a professor of psychiatry and neuroscience and the director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine in New York City. She also is the director of the Mental Health Patient Care Center at the James J. Peters VA Medical Center. Show notes: [00:02:31] Dawn begins the interview asking Rachel about her time as a child growing up in Cleveland. [00:03:17] After Ken mentions that Rachel’s father was a rabbi, Rachel explains how growing up in an observant Jewish household shaped her. [00:04:46] Rachel talks about a biology teacher who inspired her to go beyond her interests in philosophy and pursue science. [00:05:50] Dawn asks Rachel why it seems that so many scientists start out with an interest in philosophy. [00:07:16] Dawn asks Rachel why she decided to major in psychology at Touro University in New York. [00:08:16] Ken asks Rachel why she decided to attend the University of Massachusetts at Amherst after graduating from Touro University. [00:09:03] Rachel explains how she went into graduate school looking for a way to become both a psychologist and a scientist. [00:10:08] Dawn asks Rachel about something Rachel’s daughter observed about her: “You move to the beat of your own drum. You never do anything other than what the voice in your head tells you to do.” [00:11:12] Ken asks if it is true that Rachel’s first graduate advisor was not optimistic about Rachel making it through grad school. [00:12:33] Rachel tells the story of how she first met Bill Edell and walked up to him and said that she wanted to do clinical research. [00:14:38] Ken asks Rachel why she decided to do research on stress, particularly when stress wasn’t a major focus of research in the 1980s. [00:16:05] Dawn mentions that after graduating from UMass Amherst, Rachel did her postdoctoral work in biological psychiatry at Yale Medical School. Rachel met Dr. Earl Giller there, who became Rachel’s mentor and an early researcher in post-traumatic stress disorder. Rachel talks about how Dr. Giller had just completed a study on Vietnam veterans showing low cortisol levels. [00:18:40] Rachel talks about how for her post-doc at Yale she wanted to look into the biology of personality, but was told that it was a “dumb idea” for post-doc research. [00:22:06] Dawn asks about the paradox uncovered by Dr. Giller’s research into Vietnam veterans showing low cortisol levels when stress is supposed to be associated with elevated cortisol levels. Dawn goes on to ask how this finding led Rachel to interview Holocaust survivors in her hometown of Cleveland. [00:24:43] Rachel tells the story of when she talked to a group of Holocaust survivors, a woman came up to her and said: You know, Dr. Yehuda, we don’t have VA centers like your veterans do. [00:26:20] Ken asks about the program Rachel set up to help Holocaust survivors. [00:27:20] Dawn points out that in 2016 Rachel published the results of a study looking at the genes of 32 Jewish women and men. She and her colleagues at Mount Sinai studied Holocaust survivors who either had been interned in Nazi concentration camps during World War II or had witnessed or experienced torture. Rachel also looked at the genes of 22 children who were born to the Holocaust survivors after the war. Rachel discusses how the changes in the DNA of Holocaust survivors were in a way passed down to their offspring. [00:29:13] Rachel discusses the necessary caution we should take regarding our understanding of mechanisms and how effects get from one place to another, or from the experience of one generation into the biology of the next, because we simply don’t have sufficient human studies that can truly pinpoint what truly causes the effects we see. [00:32:06] Ken asks about Rachel’s realization that past effects could transform not only the narrative of a person’s life but also their physiology. [00:33:59] Dawn describes Rachel’s 2005 study with woman who were pregnant in the World Trade Center during 9/11, which showed, along with other studies, that children of traumatized parents are at risk of having similar problems as their parents due to changes occurring in the biology of the parents as a result of trauma exposure. Dawns asks about the process of epigenetic changes being transmitted to offspring, which has become known as “intergenerational transmission.” [00:36:27] Ken asks if cortisol is uniformly low, or if there is substantial variation from person to person, since one often hears of elevated cortisol levels in first responders and military populations. [00:38:43] Ken asks Rachel how she ended up at Icahn School of Medicine at Mount Sinai. [00:39:40] Ken asks about Rachel’s role as the founder and director of the Division of Traumatic Stress Studies at Mount Sinai. [00:41:20] Dawn asks Rachel to describe what happens inside a person’s body when they find themselves in a stressful situation. [00:42:47] Dawn mentions that in psychiatry and mental health, symptoms of trauma are treated as psychological, but that Rachel is finding that these problems of trauma also correlate to people having physical problems. [00:44:02] Rachel talks about her role as the Director of the Mental Health Patient Care Center at James J. Peters Veterans Affairs Medical Center in the Bronx, which she has inhabited since 2009. [00:44:58] Rachel is asked to talk about how there are only a few approved pharmacological treatments for PTSD, and no approved medications to enhance resilience. [00:46:38] Ken asks about a study Rachel published in 2013 which indicated that effective psychotherapy can be thought of as a form of “environmental regulation” which is able alter a person’s epigenetic state. [00:49:36] Ken asks how Rachel thinks the discovery of the epigenetic inheritance of trauma could change the way we approach and treat chronic health conditions, and if it is possible that much of what we are experiencing in terms of physical and mental illness as a society at large could be manifestations of trauma that has been caused by changes to epigenetic memory. [00:51:09] Rachel describes her excitement about MDMA-assisted psychotherapy for PTSD, an interest she is collaborating on with Dr. Dave Rabin, who was interviewed on STEM-Talk episode 99. [00:52:14] Dawn refers the MDMA study that Rachel and others are collaborating on with Dave, and how this study has started its phase III trial with the FDA. Rachel gives an overview of what is going on with this study and how MDMA could be licensed and become a medicine. [00:56:09] Ken asks Rachel about her quote where she said in an interview, “My career has been enhanced by the fact that early on nobody believed in PTSD. Well, now, I almost think we’ve been a victim of our own success in many ways because I think we’ve ended up really pathologizing it to a large extent.” [00:58:37] Ken comments on how he relates to Rachel, in that his early career saw him also studying something believed to be impossible, AI, and that things have now been reversed and the power of AI is often overestimated. [00:59:45] Rachel explains that she is thankful to have become a scientist, even though she enjoyed philosophy in her youth, but that if she could no longer be a scientist for some reason, she would want to become a musician. [01:00:15] “Dawn mentions that Rachel has some experience appearing on stage as a singer, such as when she performed at the Meeting of the International Society of Psychoneuroendocrinology with colleagues Thomas Neylan  and David Spiegel (interviewed on STEM-Talk episode 45).  The song Rachel sang was titled “The Grant Song,”  Dawn closes the interview asking Rachel if she wrote the humorous lyrics. Rachel Yehuda bio Learn more about IHMC STEM-Talk homepage Ken Ford bio Dawn Kernagis bio      
undefined
5 snips
Dec 17, 2019 • 1h 3min

Episode 100: Peter Attia gives an update on his views regarding longevity and health span

Today’s episode marks the 100th episode of STEM-Talk and the return of guest Peter Attia, who Ken and Dawn interviewed for episode one of STEM-Talk back in 2016. Peter is the founder of Attia Medical, a medical practice with offices in San Diego and New York City that focuses on the applied science of longevity. Peter emphasizes nutritional biochemistry, exercise physiology, sleep physiology, lipidology, pharmacology and four-system endocrinology to help people increase their lifespan and health span. Peter is the host of the podcast The Drive. He earned his M.D. from Stanford University and holds a B.S. in mechanical engineering and applied mathematics. Show notes: [00:04:44] Dawn opens the interview welcoming Peter back to the show. Dawn mentions that a lot has happened since she and Ken last interviewed Peter and points out that Peter is in the process of writing a book. [00:05:51] Ken asks Peter if it’s true that he does his best writing on long flights. [00:06:21] Dawn mentions that in 2014 Peter created Attia Medical, which is a practice with offices in San Diego and New York City, where he focuses on the applied science of longevity and optimal performance. Peter gives an overview of his practice and how he works to improve people’s healthspan and lifespan. [00:07:29] Ken asks Peter to explain the difference between a strategy and a tactic in the domain of optimization of performance and healthspan. [00:10:35] Dawn mentions that back on episode one of STEM-Talk that Peter talked about his eight drivers of longevity. Dawn asks Peter if his thinking over the past three years has changed in terms of the eight drivers. [00:12:30] Dawn asks what are some of the best lab tests in terms of longevity that people should request from their primary care physician. [00:14:25] Ken asks how Peter goes about determining optimal reference ranges to target in his patients, noting that the guidelines constituting normal are based on a sick overall population. [00:17:26] Dawn talks about how every year a new secret to longevity comes out with the force of hype behind it, but that rarely does the new so-called secret deliver. In contrast, she mentions how Peter encourages people to keep things simple and focus on nutrition, exercise and sleep. Peter explains how these three things can have the biggest impact on a person’s physical health. [00:19:35] Dawn explains that optimizing health span can be expensive, often costing upwards of $100,000 a year in tests and devices and off-label medications. She asks if Peter has any thoughts on if there is becoming a class divide in the world of healthspan and lifespan. [00:21:10] Ken explains that a primary inhibitor of BDNF is HDAC, and BHB is a powerful inhibitor of HDAC, which leads one to think that one of the mechanisms of exercise to increase BDNF is the elevation of BHB. [00:22:21] Ken mentions that the area under the curve for insulin is one of Peter’s favorite longevity markers, and asks him to talk about the concept of insulin area under the curve.  In addition to blood tests and glucose monitoring, Ken asks Peter what would be the next item of greatest interest in terms of longevity markers. [00:24:28] Dawn mentions that Peter wears an Oura Ring to monitor his sleep, and a glucose monitor to measure his blood sugar in real time. Dawn asks Peter to talk about the benefits of continuous monitoring versus short-term use for the purpose of building future behavior. [00:25:54] Dawn asks if Peter uses any other wearables besides the ones she just mentioned. [00:27:45] Dawn points out that Peter traveled to Easter Island with some friends, including David Sabatini, a guest on episode 70 of STEM-Talk. Dawn asks Peter to talk about the trip which was set up to explore first-hand the place where a group of Canadian researchers first discovered rapamycin. [00:29:13] Ken mentions that Peter is on record saying, “For me personally nothing is more interesting than rapamycin.” Peter explains what he has been learning about rapamycin and why it is so fascinating. [00:31:49] Ken says that in one of Peter’s podcasts, Peter mentioned he had been taking 5 mg of rapamycin. Ken asks what it was that informed that choice. Ken also asks Peter how he has been tracking rapamycin’s effects, and if he has any thoughts for listeners considering rapamycin. [00:33:38] Dawn asks if we are any closer to being able to accurately measure biological signals, such as mTOR activity and autophagy, than we were three years ago. [00:36:28] Peter explains his thoughts on muscle loss and fasting, and the amino acids that are important in muscles affected during a fast. [00:38:44] Ken mentions that there are a lot of misconceptions about protein consumption, particularly in the context of ketogenic diets. He mentions Valter Longo’s opinion that a diet high in protein is as bad as smoking. Peter explains his thoughts on the role of protein in health and performance. [00:41:05] Ken makes the point that the strongest viewpoints in science that have the most passion and anger behind them are often the ones with the largest error bars. [00:41:35] Dawn mentions the importance of IGF-1 and its related molecules on metabolism. She asks about the paradox when it comes to IGF-1 in terms of performance and longevity. [00:43:39] Ken mentions that the Annals of Internal Medicine published a study that made the point that eating red meat poses minimal health risks. Peter gives his thoughts on this. [00:48:39] Ken states that in addition to rapamycin and fasting, he and Peter share an interest in sauna, a practice with growing evidence for its benefits. Ken asks Peter’s opinion on the difference between infrared and traditional sauna. [00:50:03] Dawn mentions that in 2016 the Dong et al paper in Nature suggested that the limit of human longevity has been reached, and that Barbi et all published a paper in Science in 2018 that said that the mortality curve for humans flattens out once the age of 105 is reached. Peter shares his thoughts on just how long humans can live. [00:53:29] Ken mentions that a recent study from the Miller Lab suggested that metformin might inhibit mitochondrial adaptation in older adults, and that an even more recent paper out of the University of Kentucky and the University of Alabama reported that metformin significantly blunts muscle hypertrophy in response to resistance training. Peter gives his thoughts on this and why he stopped taking metformin. [00:55:36] Peter shares his concerns about generic metformin, as well as his recent interview with Katherine Eban about the fraud in the generic drug industry. [00:57:15] Ken mentions that Peter is a proponent of fasting, and is involved with the Zero app. Ken asks if the benefits of fasting can be thought of in relationship to ApoB levels. [00:59:18] Ken asks Peter to describe what he sees as the most interesting question he doesn’t yet have an answer to, but believes is eventually possible to know. [01:00:28] Dawn ends the interview by asking Peter if there is one thing that he did not believe three years ago that he now thinks is likely to be true. Links: Peter Attia bio Learn more about IHMC STEM-Talk homepage Ken Ford bio Dawn Kernagis bio  
undefined
Nov 26, 2019 • 1h 22min

Episode 99 : Dave Rabin talks about how psychedelics and wearable devices can help improve people’s lives

Dr. David Rabin is the chief innovation officer and co-founder of Apollo Neuroscience. He also is the co-inventor of Apollo, a wearable device designed to improve focus, sleep and access to meditative states by gently delivering layered vibrations to the skin. Dave is a board-certified psychiatrist and translational neuroscientist who for the past decade has been studying resilience and the impact of chronic stress on humans. He received his MD in medicine and Ph.D. in neuroscience from Albany Medical College in Albany, New York. He trained in psychiatry at Western Psychiatric Institute and Clinic at the University of Pittsburgh Medical Center. Dave also has organized the world’s largest controlled study of psychedelic medicines and is well-known for his research into MDMA and its potential to treat posttraumatic stress disorder along with other disorders. Show notes [00:03:06] Dawn opens the interview mentioning that David grew up in California and asking him about an insatiable need he had as a child to understand why people were the way that they were. [00:04:18] David talks about how the vivid and frequent dreams he had as a child played a role in his decision to study consciousness and neuroscience. [00:07:33] Dawn mentions that in high school Dave told his father that he wanted to study consciousness; however, Dave’s father suggested that he study something more tangible and quantifiable instead. Dave explains how this led him to spend the summer between his junior and senior year of high school at Rockefeller University. [00:12:08] Ken asks why Dave decided to move across the country to Albany Medical College, where he received his MD in medicine and Ph.D. in Neuroscience. [00:14:01] Dave gives an overview of the research he did, while working on his Ph.D., in emotional salience and how people interpret different stimuli as either threatening or safe. An area of research informed by his reading of evolutionary psychology, and the study of touch as an evolutionarily conserved stimulator of the safety pathway. [00:17:58] Ken asks about how Dave decided to go into psychiatry at Western Psychiatric Institute and Clinic at the University of Pittsburg Medical Center, where he focused on treatment-resistant mental illnesses. [00:20:47] Dawn mentions Dave’s work with Greg Siegel. Dawn asks about this work and how it led Dave to become serious about studying consciousness, altered states of consciousness, and the potential use of these altered states to facilitate healing. [00:24:26] Ken talks about MDMA, or 3,4-Methyl​enedioxy​methamphetamine, a psychoactive drug commonly known as ecstasy or molly.  He explains that MDMA has been shown to facilitate the release of oxytocin, which increases levels of empathy and closeness while dampening fear-related amygdala activity. This results in an overall decrease in stress response and social anxiety. Ken asks Dave to talk about MDMA’s potential to treat PTSD (posttraumatic stress disorder) along with other disorders. [00:27:37] Ken asks if Dave has seen any improvements in heart rate variability (HRV) post MDMA treatments. [00:28:37] Dawn mentions that Dave is part of the world’s largest controlled study of psychedelic medicines. She goes on to explain that these medicines, like LSD and MDMA and even psilocybin, which comes from mushrooms, were used to treat mental and emotional trauma from the 1950s to the ‘70s.  Due to the abuses that occurred during this time, the use as well as research on psychedelic medicines in U.S. were shut down. With a shift towards a renewed interest in these medicines, Dawn asks about this study and if Dave could give a background on psychedelic medicine. [00:32:34] Dave talks about the epigenetic trial, being conducted in phase three of the MDMA study, where DNA samples are collected before and after use, to determine the epigenetic regulation of stress-response genes. [00:41:30] Ken asks about psilocybin, which is a naturally occurring psychedelic produced by more than 200 species of mushrooms. Ken asks Dave to explain how psilocybin is different from MDMA, both chemically and experientially. [00:45:45] Dave discusses the use of ecstasy and the debate around the safety of MDMA, and how compared to stimulants such as cocaine, amphetamine and methamphetamine, addiction to MDMA is very rare. [00:48:47] Dawn explains that psychedelics are, to this day, illegal in the U.S., and further states that STEM-Talk is not advocating the use of these or any illegal substances, before asking Dave about the changing legal status of psychedelics. [00:49:51] Dawn asks about the use of cannabidiol (CBD) for management of symptoms for illnesses such as PTSD and pain-management. [00:54:17] Ken mentions that Dave has spent the last several years developing a technology called Apollo, which is intended to help people make changes more effectively. Given the research and study Dave has done into stress, meditation and athletic performance, and why some people are more resilient than others, Ken asks Dave what he has learned from all this and how it led to the Apollo technology. [00:57:31] Ken asks if the hypervigilance people have to text alerts and emails and phone vibrations and news alerts and the constant bombardment of noise and stimuli is conditioning our bodies to be in a hyper-stressed state all the time. [00:59:26] Ken asks how to retrain the nervous system to become more balanced between our sympathetic and parasympathetic symptoms without the use of psychedelics. [01:02:37] Dawn asks about cognitive patterns and the way people think about their lives, such as the tendency to take challenges personally and think “why me?” while others tend to see challenges as an opportunity for growth. [01:05:35] Dave talks about heart-rate variability (HRV) and why he considers it one of the more important findings about resilience that has been made in the past 15 years. [01:09:19] Dawn asks what a good range for HRV is, or if there is a significant degree of variation across healthy people. [01:10:31] Dave explains the Apollo wearable device in depth, and how and why it works. [01:11:57] Ken asks if there have been pilot studies with children for the Apollo device. [01:14:14] Dawn mentions that Dave’s wife Kathryn was the one who came up with the idea to create the company Apollo Neuroscience. Dave tells the story behind that. [01:15:37] Ken mentions that David and Kathryn are in in the process of launching Apollo, and that the devices will start shipping in January. [01:15:50] Dawn asks, given Dave’s study of stress and the pervasiveness of technology in our modern world and its role in our levels of stress, how he deals with stress on a day-to-day basis. [01:18:12] Dawn mentions that Dave went to work for his wife this last year and asks, aside from their working relationship, what the two of them do for fun. Links: Dave Rabin bio Learn more about IHMC STEM-Talk homepage  Ken Ford bio Dawn Kernagis bio  
undefined
6 snips
Nov 5, 2019 • 1h 40min

Episode 98: Steven Austad talks about aging and preserving human health

Our guest today is Dr. Steven Austad who studies virtually every aspect of aging. He is a distinguished professor and chair of the Department of Biology at the University of Alabama, Birmingham. In addition to being recognized for his aging and longevity research, Steve is also well-known for his background as a New York City cab driver, newspaper reporter and a lion trainer who then decided to become a biologist. His research today involves developing lifestyle and pharmacological approaches to improving and preserving human health. He is particularly focused on figuring out why different species age at different rates. Steve is the author of more than 190 scientific articles. His book, “Why We Age: What Science Is Discovering about the Body’s Journey Through Life,” has been translated into nine languages. He also writes newspaper columns and has written for publications like Natural History magazine, Scientific American and International Wildlife. Show notes: [00:02:53] Dawn opens the interview mentioning that Steve was born in Southern California, but that his family moved around so much, that he ended up attending around 20 grade schools. Steve explains that his father bought a travel trailer and moved the family around the country. [00:03:57] Steve talks about how even though he was shy and introverted as a kid, he found a way to fit in with his classmates. [00:04:40] Ken mentions how Steve’s career went through several reinventions before settling into a career in science. Among the various occupations Steve had were: a newspaper reporter, training lions and tigers for television and movies, and taxi driving. Ken asks Steve how he became a taxi driver. [00:06:01] Steve talks about his time on the West Coast in Portland working as a newspaper reporter for the Oregonian. [00:07:48] Dawn asks how it was that Tippi Hedren and Melanie Griffith had something to do with Steve becoming a lion trainer. [00:14:39] Ken asks Steve about the suicidal duck whose reckless abandonment nearly resulted in Steve’s death at the hands of one of the lions he was training. [00:19:21] Steve discusses why his fascination with animal behavior lead him to California State University to major in biology. [00:23:24] Dawn asks what took Steve to the University of New Mexico for his postdoc. [00:28:16] Ken asks how Steve landed his job as assistant professor in the Department of Organismic and Evolutionary Biology at Harvard University in 1986. [00:29:59] Dawn mentions that Steve discovered that opossums of the predator-free barrier island of Sapelo Island lived 25 percent longer than their cousins on the mainland of Georgia. Steve discusses this and explains how this discovery played a role in his future research. [00:34:13] Dawn points out that Steve left Harvard for the University of Idaho where he became a full professor and then next went the University of Texas. Dawn asks Steve about accepting  a position in 2014 at the University of Alabama, Birmingham. [00:41:32] Steve discusses his research into lifespan and healthspan and longevity and why some species age at different rates, with a particular interest in long-lived organisms like quahogs clams and hydra. He goes on to explain how this research led to what he refers to as the “Longevity Quotient.” [00:48:42] Ken mentions that as a former Rhode Islander, he spent some time digging Quahogs and eating them. [00:53:14] Steve gives an overview of how dietary restriction studies are performed on mice. [00:59:39] Ken mentions that from Steve’s description it seems that modern humans are becoming more and more like laboratory mice. [01:02:53] Ken mentions STEM-Talk episode 79 where Satchin Panda talks about time-restricted eating, and episode 7 where Mark Matson talks about intermittent fasting. Ken goes on to say that Mark made the point that the benefits of time-restricted eating or intermittent fasting is that it puts the organism, particularly the human, in a state of ketosis. [01:04:09] Steve talks about the differences in the maximum lifespans of males and females in both humans and other animals. [01:08:42] Ken recommends STEM-Talk episode 67 with Doug Wallace for listeners interested in hearing more about mitochondria. [01:09:44] Dawn asks about metformin, which is a drug that many people believe has the potential to increase our healthspan and lifespan. She asks why it is that we’re not all taking metformin and if it really has such potential. She further asks about the status of the Targeting Aging With Metformin (TAME) trial. [01:13:39] Ken mentions a recent study coming from the Miller lab, that suggested metformin might inhibit mitochondrial adaptations to exercise in older adults. He goes on to mention an even more recent paper out of the University of Kentucky and the University of Alabama, Birmingham has reported that metformin blunts muscle hypertrophy in response to resistance exercise training in older adults. Ken also mentions Steve’s continued interest in rapamycin and its effect on the health span of animals. Ken asks what Steve has learned and if rapamycin would still be his first choice for testing for a drug to target aging. [01:20:08] Ken asks about the optimal and most efficacious dose of rapamycin for humans. [01:21:10] Dawn mentions a paper Steve co-authored with Tuck Finch, discussing the role of the different APOE isoforms. Dawn asks about the ancestral isoform and why we see different isoform distributions today compared to hundreds of thousands of years ago. [01:24:59] Dawna asks why we see different isoform distributions between different populations around the globe. [01:26:29] Dawn asks how much of a role lifestyle versus genetics plays in healthspan and lifespan. [01:28:58] Steve talks about of Fauja Singh, who is 108 and didn’t start distance running until he was in his 80s, and who ran a marathon when he was 101. [01:32:17] Ken asks if Steve is still as confident as he was in 2016 when he made a bet with Olshansky over whether there will be one or more 150-year-old human by the year 2150. [01:34:15] Ken asks why we haven’t seen someone exceed Jeanne Calment’s record age of 122 years that she reached in 1997. [01:36:04] Dawn mentions that Steve continues to write articles and columns for newspapers as well as other news outlets. In addition to this Steve also has a website called, “Let’s Talk Science?” where an assortment of his newspaper columns and other writings can be found. [01:37:47] Dawn closes the interview suggesting that Steve might want to explore writing a novel about a young newspaper reporter who ends up driving a Mercedes across California with a lion in the backseat, who then finds himself in a Hollywood mansion living with Tippi Hedrin and Melanie Griffin and watching over the lions and cheetahs that run through the house. Dawn suggests that has the makings of a good book. Links: Austad’s University of Alabama, Birmingham bio Let’s Talk Science Learn more about IHMC STEM-Talk homepage Ken Ford bio Dawn Kernagis bio
undefined
Oct 15, 2019 • 1h 19min

Episode 97: Francesca Rossi talks about AI ethics and the development of new AI systems

Our guest today is Francesca Rossi,  who for the past three years has been an AI Ethics Global Leader at IBM Research as well as an IBM Distinguished Research Staff Member. Prior to her time at IBM, she was a professor of computer science at the University of Padova, Italy. Francesca’s AI research interests include constraint reasoning, preferences, multi-agent systems, computational social choice, and collective decision making. Much of her research today is focused on the future of artificial intelligence and the ethical issues surrounding the development and behavior of AI systems. She is a fellow of both the worldwide association of AI (AAAI) and of the European Association of AI. She also has been president of the International Joint Conference on AI and the editor in chief of the Journal of AI Research. Sitting in for Dawn during today’s interview is IHMC colleague Brent Venable, who recently was named the inaugural director of a new Ph.D. program in Intelligent Systems and Robotics that is a partnership between IHMC and the University of West Florida. Brent is a graduate of the University of Padova and had Francesca as her academic advisor. Show notes: [00:03:25] Brent opens the interview asking Francesca where she grew up in Italy. [00:03:51] Brent mentions that Francesca was a curious child, who was fascinated with the moon landing. Brent asks what else Francesca was interested in as a child. [00:05:01] Francesca explains that if she were to stumble across a time machine she would be interested in going forward in time rather than backwards. [00:05:41] Ken asks why Francesca decided to study computer science in 1981when the field was relatively new. [00:07:22] Francesca discusses the one class in her academic career that stumped her, despite her good grades in every other subject. [00:08:36] Ken mentions that Francesca ended up in Austin, Texas after obtaining her degree in computer science, and asks what it was that lead her to the University of Texas and what research she did there. [00:11:40] Brent asks why Francesca decided to go back to Pisa after Texas to work on her Ph.D. [00:13:23] Brent mentions that after Francesca’s Ph.D., she moved to the University of Padova, where she worked for the next 20 years. Brent asks about the work that Francesca did in this period, particularly her seminal work on preferences for intelligent systems. [00:15:17] Ken discusses how Francesca became Brent’s academic advisor at Padova. Ken mentions that he has heard that the two of them had so much fun working together, that they did as much laughing as research during their time at Padova. He asks the two of them if that could possibly be true. [00:17:41] Francesca talks about the sabbatical she took to the Radcliff Institute. [00:22:00] Brent asks about an article in the Wall Street Journal that featured Francesca as well as a senior manager at IBM and one of the founders of Skype and how the article played a role in Francesca’s decision to move to the United States. [00:23:41] Francesca’s title at IBM is “Global Ethics Leader.” Brent asks Francesca to describe what the job entails. [00:30:00] Ken asks what Francesca envisions as the likely future of AI, and what she hopes for the future of AI. [00:31:54] Francesca discusses how we sometimes craft our visions for the future around our current technology, and that she believes that the proper approach should be to build our technologies around our visions for the future. [00:34:37] Brent asks Francesca for her thoughts on whether or not the fear of robots and AI going rogue and hurting people is a legitimate one, and what she thinks about the government adopting AI legislation. [00:38:23] Francesca gives her thoughts on the fears that AI will one day replace human workers. [00:41:43] Brent mentions that Matt Johnson, interviewed on episode 86 of STEM-Talk, had an article in AI magazine where he discussed human machine teaming, and said that humans and AI should work together the way two musicians do when playing a duet. [00:44:11] Ken asks about the current predominance of machine learning as opposed to traditional AI, otherwise known as symbolic AI, and if the area of preferences that Francesca has pioneered could be a potential candidate for bringing these two areas of AI together. [00:47:55] Brent asks if we ever decided to one day replace a judge with a deep learning algorithm, would AI be prone to discrimination based on the dataset that the deep-learning algorithm has been given to learn from. [00:52:35] Ken asks if there are ways to hold the people and the companies that design intelligent systems accountable for the decisions that they make? [00:55:29] Ken mentions that tech companies often shift blame to algorithms for mistakes that were a fault of humans whether intentional or unintentional. He asks about the growing concern of biases both consciously and unconsciously being imbedded into algorithms by the humans who make them. [01:00:34] In ascribing values to intelligent machines to abide by, Ken asks whose values should be used, as different cultures have different values as well as different ethical codes of conduct. [01:04:42] Brent asks about Francesca’s involvement with The Future of Life Institute, which leads Francesca to discuss Max Tegmark’s book “Life 3.0.” [01:08:11] Brent asks about another initiative Francesca is involved in called Partnership for AI. [01:10:52] Ken mentions that Francesca is the conference chair  for the 34th Annual AAAI Conference on Artificial Intelligence, which will take place in New York City in February. Ken asks what the submissions currently look like and also to talk about the health of the field. [01:13:49] Brent asks what Francesca does with her spare time. [01:15:11] Ken asks Francesca why he was told to reassure her that the STEM-Talk staff would use a photograph of her and not a photograph of “The Terminator” on the STEM-Talk home page next to her episode. Links: Francesca Rossi IBM bio Learn more about IHMC STEM-Talk homepage  Ken Ford bio Dawn Kernagis bio      

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode